Logo image of CERC

Cerecor Inc (CERC) Stock Fundamental Analysis

NASDAQ:CERC - Nasdaq -

2.93  -0.05 (-1.68%)

After market: 2.9468 +0.02 (+0.57%)

Fundamental Rating

2

CERC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. CERC may be in some trouble as it scores bad on both profitability and health. CERC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CERC has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -119.98%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1201.64%
PM (TTM) -1194.83%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

CERC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CERC has an Altman-Z score of -4.37. This is a bad value and indicates that CERC is not financially healthy and even has some risk of bankruptcy.
CERC has a Debt/Equity ratio of 0.79. This is a neutral value indicating CERC is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -4.37
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.19 indicates that CERC has no problem at all paying its short term obligations.
CERC has a Quick Ratio of 2.18. This indicates that CERC is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.18

More info and screens

3

3. Growth

3.1 Past

CERC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.12%.
CERC shows a decrease in Revenue. In the last year, the revenue decreased by -6.39%.
The Revenue for CERC have been decreasing by -37.78% on average. This is quite bad
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-37.78%
Revenue growth 5YN/A
Sales Q2Q%150.78%

3.2 Future

CERC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.94% yearly.
Based on estimates for the next years, CERC will show a very strong growth in Revenue. The Revenue will grow by 120.79% on average per year.
EPS Next Y4.09%
EPS Next 2Y11.13%
EPS Next 3Y16.75%
EPS Next 5Y7.94%
Revenue Next Year-12.27%
Revenue Next 2Y17.22%
Revenue Next 3Y104.26%
Revenue Next 5Y120.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CERC Yearly Revenue VS EstimatesCERC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CERC Yearly EPS VS EstimatesCERC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERC Price Earnings VS Forward Price EarningsCERC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.42
CERC Per share dataCERC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as CERC's earnings are expected to grow with 16.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.13%
EPS Next 3Y16.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Cerecor Inc

NASDAQ:CERC (8/25/2021, 8:25:06 PM)

After market: 2.9468 +0.02 (+0.57%)

2.93

-0.05 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.01%
Inst Owner Change0%
Ins Owners3.95%
Ins Owner Change0%
Market Cap281.31M
Analysts100
Price Target6.63 (126.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.72
P/FCF N/A
P/OCF N/A
P/B 13.03
P/tB N/A
EV/EBITDA -3.42
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS0.22
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1201.64%
PM (TTM) -1194.83%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.18
Altman-Z -4.37
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
EPS Next Y4.09%
EPS Next 2Y11.13%
EPS Next 3Y16.75%
EPS Next 5Y7.94%
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-37.78%
Revenue growth 5YN/A
Sales Q2Q%150.78%
Revenue Next Year-12.27%
Revenue Next 2Y17.22%
Revenue Next 3Y104.26%
Revenue Next 5Y120.79%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A